Shenzhen Sciprogen Bio-pharmaceutical
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
RD01 (PEG-EPO)No recent activity | Phase 2 | Erythropoietin receptor (EPO-R)Biologic (subtype unspecified) | Chronic Kidney Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.